N. Shand

发表

Local inflammation and devascularization — in vivo mechanisms of the “bystander effect” in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma

F. Floeth, H. Bojar, H. Prisack, 2001, Cancer Gene Therapy.

A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group.

L. Mariani, A. Sorensen, M. Bernstein, 1999, Human gene therapy.

A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir

L. Mariani, A. Sorensen, A. Gianella-Borradori, 1999 .

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

E. Raymond, M. Campone, F. Calvo, 2009, British Journal of Cancer.

Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM.

A. D. Van den Abbeele, G. Demetri, J. Kovarik, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors

Suzanne F. Jones, J. Baselga, F. Rojo, 2005 .

Cyclosporin A (Sandimmun®) in autoimmune disorders

N. Shand, B. Graffenried, P. Timonen, 1989 .

Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers.

I. Judson, C. Brock, N. Shand, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC)

T. Roskams, S. Dimitrijević, E. Lerut, 2005 .

A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update

J. Blay, J. Fletcher, G. Demetri, 2005 .

Sandimmun (cyclosporin A): mode of action and clinical results in rheumatoid arthritis.

N. Shand, B. Richardson, 1988, Scandinavian journal of rheumatology. Supplement.

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

Suzanne F. Jones, F. J. Ramos, J. Baselga, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy.

P. Lu, T. Fitzgerald, N. Shand, 1999, Human gene therapy.

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

H. Lane, E. Raymond, J. Kovarik, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

Suzanne F. Jones, Ian Judson, D. Rea, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Summary of results in patients with metastatic renal cell cancer (RCC) from phase I studies of RAD001 (everolimus).

J. Baselga, I. Judson, H. Burris, 2006, Journal of Clinical Oncology.

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

H. Lane, E. Raymond, J. Kovarik, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.